Virus cocktail takes on tough liver tumors
NCT ID NCT07381309
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether injecting an oncolytic virus (H101) directly into liver tumors, along with radiation, chemotherapy, targeted therapy, and immunotherapy, can shrink or control colorectal cancer that has spread to the liver and cannot be removed by surgery. The study will enroll 114 adults with a specific type of colorectal cancer (MSS/pMMR). The goal is to see if this powerful combination improves response rates and helps patients live longer without their cancer growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oncolytic virus H101
What this could lead to
If successful, this combination approach could offer a new treatment option for people with hard-to-treat colorectal cancer that has spread to the liver.
What could go wrong
This is an early phase 2 trial with only 114 participants, so results may not apply to everyone. Combining multiple therapies also raises the risk of side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China